Endomagnetics appoints chairman

Dr John Gonzalez joins firm from Alice Ventures

Endomagnetics, a UK developer of advanced magnetic sensing technology for use in cancer treatment, has appointed Dr John Gonzalez as chairman.

Gonzalez brings with him wide experience in healthcare and life sciences in business development, and latterly in medtech investment.

Gonzalez joins Endomagnetics from Alice Ventures where he was life sciences partner, responsible for all aspects of investments in biotech, medical devices and specialist pharmaceuticals. He has served on the board of 10 medtech companies in the UK, Europe and the US.

Previously he has held senior positions with PowderJect Pharmaceuticals and SmithKline Beecham.

Endomagnetics has recently achieved CE Mark approval for its first product, the SentiMag, an ultrasensitive hand-held probe that is capable of detecting magnetic materials in the human body and is used to locate lymph nodes in the treatment of cancer.

You may also like

Research & Development

Amolyt receives FDA fast track designation for hypoparathyroidism drug

The therapeutic has been awarded the fast track designation owing to the Phase III Calypso trial, which showed promising efficacy and safety features
Analysis

A new generation of mechanical surface testing platforms

The Step series allows high precision readings and easy transitioning between methods
Research & Development

OGT launches new SureSeq myeloid fusion panel drive myeloid cancer research

The assay enables users to integrate research techniques with a single, streamlined NGS process, expediting the process
Regulatory

Compact process thermostat for efficient temperature control in the lab

The Petite Fleur allows for laboratory reactor temperature control between -40 °C to +200 °C with a 480W refrigeration capacity
Research & Development

Lonza's AI-enabled small molecule development tool launches

The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Manufacturing

Miltenyi Biotec and MiLaboratories collaborate to advance next-generation therapies

Miltenyi Biotec will commercialise MiLaboratories' RNA kit technology for immune sequencing, facilitating advances in the field of personalised medicine
Research & Development

Abzena launches EpiScreen 2.0 to assist the development of complex biologics and bioconjugates

The updated platform delivers an advanced range of immune response measurements, while also providing information on mechanism-of-action and specificity
Subscribe now